RAS: target for cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• RAS proteins are key regulators of cell signaling pathways involved in cell growth, proliferation, and differentiation.
• Aberrant RAS signaling, often due to activating mutations found in ~30% of human cancers, drives malignant transformation and tumor maintenance.
• RAS proteins are therefore considered a critical target for novel anticancer therapies.

Purpose of the Study:

• To review the current therapeutic strategies targeting RAS proteins for cancer treatment.
• To discuss the different classes of anti-RAS agents currently under clinical evaluation.
• To highlight the potential and future directions for RAS-targeted anticancer drug development.

Main Methods:

• Review of existing literature on RAS signaling and targeted therapies.
• Analysis of pharmacologic inhibitors targeting different aspects of RAS pathway.
• Evaluation of clinical trial data for anti-RAS agents.

Main Results:

• Activating RAS mutations are prevalent in human cancers, underscoring RAS as a viable therapeutic target.
• Multiple anti-RAS strategies are in clinical development, including inhibitors of membrane association, downstream signaling, upstream pathways, and RAS expression.
• Several novel therapeutic agents targeting RAS are demonstrating promising clinical outcomes.

Conclusions:

• Targeting RAS represents a significant and evolving strategy in cancer therapy.
• The diverse range of anti-RAS agents offers multiple avenues for intervention in various cancer types.
• Continued research and clinical evaluation of these agents hold substantial hope for improved cancer treatment outcomes.